Seek urgent medical advice (contact your GP or NHS 111) if you experience: Severe or persistent abdominal pain, especially if accompanied by vomiting Persistent vomiting or inability to keep fluids down Signs of dehydration (extreme thirst, dark urine, dizziness) Sudden severe upper abdominal pain radiating to the back (possible pancreatitis) Severe right upper abdominal pain (possible gallstones) Severe bloating with vomiting and no passage of stool or gas (possible obstruction) Persistent or severe gastrointestinal symptoms may indicate the need for dose adjustment or, rarely, discontinuation of therapy
Flavored Teas: Hot or iced, explore herbal blends, black teas, or fruit-infused options for a warm or refreshing treat
Research shows that protein intake during GLP-1 therapy is critical, but glycine adds an additional layer of protection at the cellular level
You may find that your blood sugar levels are more controlled, your blood pressure falls, and you sleep better
Semaglutide 2.4 mg (Wegovy) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity and starting body mass index (BMI)
